B
BiomACS provides a proprietary screening platform that semi-automatically tests thousands of material surface variations using relevant tissue cells. This technology identifies optimal surface properties like structure, wettability, and stiffness to reduce adverse cellular reactions to medical implants. The platform accelerates the development of safer medical devices by efficiently screening for material compatibility in both in vitro and in vivo applications.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- BiomACS provides a proprietary, semi-automated screening platform that tests thousands of material surface property combinations using relevant tissue cells. This technology identifies optimal surface characteristics to mitigate adverse cellular reactions to medical implants, accelerating the development of safer devices. The platform reduces negative biological effects by optimizing surface structure, wettability, and stiffness for improved tissue integration and reduced complications.